You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: COLORADO RESEARCH PARTNERS LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Satellite Drag Physical Model Module for a Near Real Time Operation Test Bed

    SBC: ATMOSPHERIC & SPACE TECHNOLOGY RESEARCH ASSOCIATES LLC            Topic: AF11BT29

    ABSTRACT: The Air Force seeks to improve the accuracy of orbit specification and of 72-h orbit predictions beyond present capabilities. Thermospheric neutral density and satellite ballistic coefficient strongly impact satellite drag estimation, which is a leading source of error in orbit predictions in LEO. The goal of this Phase II project is to develop a satellite drag specification capability ...

    STTR Phase II 2014 Department of DefenseAir Force
  3. Prediction and Measurement of the Soot Build-Up in Film-Cooled Rocket Engines

    SBC: SIERRA ENGINEERING, INC.            Topic: AF15AT21

    This Phase II STTR effort is focused on generating the data necessary to identify the phenomenology that produces carbon deposition within kerosene film cooled rocket engines.This data is essential to guide the model development and validation process.Program outputs will be both data and a physics-based model for carbon deposition.

    STTR Phase II 2017 Department of DefenseAir Force
  4. Versatile and Robust Three-Dimensional Software for Multi-Fluid Plasma Modeling

    SBC: TECH-X CORPORATION            Topic: AF11BT08

    ABSTRACT: In this STTR Tech-X corporation in partnership with the University of Washington will improve a commercial plasma modeling tool, Nautilus, for simulating high-temperature multi-fluid plasmas for problems such as the field reversed configuration, dense plasma focus and the plasma opening switch. Semi-implicit algorithms will be implemented in Nautilus so that the speed of light and elec ...

    STTR Phase II 2014 Department of DefenseAir Force
  5. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Clinical Screening Platform for Type Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    Abstract A major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to disease Current criteria involve HLA haplotype and the presence of auto antibodies AA Genome wide associated studies GWAS revealed only immune associated genes including HLA as T D predictors The ability to differentiate from other diseases was very limited Pre type diabetes p T ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Screening for the autoimmune component of multiple sclerosis

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Multiple Sclerosis is an inflammatory neurodegenerative disease with autoimmune components that exacerbate and potentially initiate the disease Diagnosis is invasive time consuming relatively expensive and extremely difficult In fact no clear diagnostic test yet exist A major concern is that MS symptoms are identical to the symptoms of numerous other neurologic diseases OND as well as some ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a small peptide to control autoimmune inflammation in type diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Abstract Type Diabetes T D affects an ever growing population While this disease typically has been associated with juveniles the disease in adult populations is rapidly increasing The defining clinical component is insulin loss which occurs because of sustained inflammation in the islets At present there is no means to prevent or reverse insulin loss A major inflammatory pathway in T D ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Novel HDAC Inhibitors for Treatment of Hemoglobinopathies

    SBC: CETYA THERAPEUTICS, INC.            Topic: NHLBI

    Project Summary Induction of normal but developmentally silenced fetal globin expression reduces anemia and ameliorates clinical severity in the beta hemoglobinopathies HDACs and are components of the NURD repressor complex which promotes silencing of fetal globin in adult cells Prior generation HDAC inhibitors have increased fetal globin in patients but had limitations for pharmaceu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government